Clinical Trials, Second Edition, offers those engaged in clinical trial design a valuable and practical guide. This book takes an integrated approach to incorporate biomedical science, laboratory data of human study, endpoint specification, legal and regulatory aspects and much more with the fundamentals of clinical trial design. It provides an overview of the design options along with the specific details of trial design and offers guidance on how to make appropriate choices. Full of numerous examples and now containing actual decisions from FDA reviewers to better inform trial design, the 2nd edition of Clinical Trials is a musthave resource for early and midcareer researchers and clinicians who design and conduct clinical trials.
1. Introduction - p. Page xiv 2. Abbreviations and Definitions - p. Page xvii 3. Biographies - p. Page xx 4. List of Illustrations - p. Page xxiii 5. List of Tables - p. Page xxiv 6. Chapter 1 : Origins of Drugs - p. Page xxiv 7. Chapter 2 : Clinical Trial Design - p. Page 30 8. Chapter 3 : Run-In Period - p. Page 68 9. Chapter 4 : Inclusion/Exclusion Criteria, Stratification, and Subgroups—Part I - p. Page 81 10. Chapter 5 : Inclusion/Exclusion Criteria, Stratification, and Subgroups—Part II - p. Page 113 11. Chapter 6 : Blinding, Randomization, and Allocation - p. Page 132 12. Chapter 7 : Placebo Arm as Part of Clinical Trial Design - p. Page 153 13. Chapter 8 : Intent-to-Treat Analysis Versus Per Protocol Analysis - p. Page 172 14. Chapter 9 : Biostatistics—Part I - p. Page 201 15. Chapter 10 : Biostatistics—Part II - p. Page 226 16. Chapter 11 : Introduction to Endpoints - p. Page 245 17. Chapter 12 : Oncology Endpoint—Objective Response - p. Page 252 18. Chapter 13 : Oncology Endpoints: Overall Survival and Progression-Free Survival - p. Page 268 19. Chapter 14 : Oncology Endpoints: Time to Progression - p. Page 288 20. Chapter 15 : Oncology Endpoint: Disease-Free Survival - p. Page 301 21. Chapter 16 : Oncology Endpoint: Time to Distant Metastasis - p. Page 312 22. Chapter 17 : Neoadjuvant Therapy Versus Adjuvant Therapy - p. Page 319 23. Chapter 18 : Hematological Cancers - p. Page 330 24. Chapter 19 : Biomarkers - p. Page 376 25. Chapter 20 : Endpoints for Immune Diseases - p. Page 419 26. Chapter 21 : Endpoints for Infections - p. Page 436 27. Chapter 22 : Health-Related Quality of Life Tools—Oncology - p. Page 450 28. Chapter 23 : Health-Related Quality-of-Life Tools—Immune Disorders - p. Page 468 29. Chapter 24 : Health-Related Quality-of-Life Tools—Infections - p. Page 477 30. Chapter 25 : Drug Safety - p. Page 482 31. Chapter 26 : Mechanism of Action of Diseases and Drugs—Part I - p. Page 568 32. Chapter 27 : Mechanism of Action—Part II (Cancer) - p. Page 594 33. Chapter 28 : Mechanism of Action—Part III (Immune Disorders) - p. Page 609 34. Chapter 29 : Mechanisms of Action—Part IV (Infections) - p. Page 633 35. Chapter 30 : Consent Forms - p. Page 662 36. Chapter 31 : Package Inserts - p. Page 687 37. Chapter 32 : Warning Letters - p. Page 718 38. Chapter 33 : Regulatory Approval - p. Page 779 39. Chapter 34 : Patents - p. Page 828 40. Index - p. Page 845
Clinical Trials, Second Edition, offers those engaged in clinical trial design a valuable and practical guide. This book takes an integrated approach to incorporate biomedical science, laboratory data of human study, endpoint specification, legal and regulatory aspects and much more with the fundamentals of clinical trial design. It provides an overview of the design options along with the specific details of trial design and offers guidance on how to make appropriate choices. Full of numerous examples and now containing actual decisions from FDA reviewers to better inform trial design, the 2nd edition of Clinical Trials is a musthave resource for early and midcareer researchers and clinicians who design and conduct clinical trials.
1. Introduction - p. Page xiv 2. Abbreviations and Definitions - p. Page xvii 3. Biographies - p. Page xx 4. List of Illustrations - p. Page xxiii 5. List of Tables - p. Page xxiv 6. Chapter 1 : Origins of Drugs - p. Page xxiv 7. Chapter 2 : Clinical Trial Design - p. Page 30 8. Chapter 3 : Run-In Period - p. Page 68 9. Chapter 4 : Inclusion/Exclusion Criteria, Stratification, and Subgroups—Part I - p. Page 81 10. Chapter 5 : Inclusion/Exclusion Criteria, Stratification, and Subgroups—Part II - p. Page 113 11. Chapter 6 : Blinding, Randomization, and Allocation - p. Page 132 12. Chapter 7 : Placebo Arm as Part of Clinical Trial Design - p. Page 153 13. Chapter 8 : Intent-to-Treat Analysis Versus Per Protocol Analysis - p. Page 172 14. Chapter 9 : Biostatistics—Part I - p. Page 201 15. Chapter 10 : Biostatistics—Part II - p. Page 226 16. Chapter 11 : Introduction to Endpoints - p. Page 245 17. Chapter 12 : Oncology Endpoint—Objective Response - p. Page 252 18. Chapter 13 : Oncology Endpoints: Overall Survival and Progression-Free Survival - p. Page 268 19. Chapter 14 : Oncology Endpoints: Time to Progression - p. Page 288 20. Chapter 15 : Oncology Endpoint: Disease-Free Survival - p. Page 301 21. Chapter 16 : Oncology Endpoint: Time to Distant Metastasis - p. Page 312 22. Chapter 17 : Neoadjuvant Therapy Versus Adjuvant Therapy - p. Page 319 23. Chapter 18 : Hematological Cancers - p. Page 330 24. Chapter 19 : Biomarkers - p. Page 376 25. Chapter 20 : Endpoints for Immune Diseases - p. Page 419 26. Chapter 21 : Endpoints for Infections - p. Page 436 27. Chapter 22 : Health-Related Quality of Life Tools—Oncology - p. Page 450 28. Chapter 23 : Health-Related Quality-of-Life Tools—Immune Disorders - p. Page 468 29. Chapter 24 : Health-Related Quality-of-Life Tools—Infections - p. Page 477 30. Chapter 25 : Drug Safety - p. Page 482 31. Chapter 26 : Mechanism of Action of Diseases and Drugs—Part I - p. Page 568 32. Chapter 27 : Mechanism of Action—Part II (Cancer) - p. Page 594 33. Chapter 28 : Mechanism of Action—Part III (Immune Disorders) - p. Page 609 34. Chapter 29 : Mechanisms of Action—Part IV (Infections) - p. Page 633 35. Chapter 30 : Consent Forms - p. Page 662 36. Chapter 31 : Package Inserts - p. Page 687 37. Chapter 32 : Warning Letters - p. Page 718 38. Chapter 33 : Regulatory Approval - p. Page 779 39. Chapter 34 : Patents - p. Page 828 40. Index - p. Page 845